Pharma stocks crater as investors brace for litigation charges

Pharma stocks crater as investors brace for litigation charges

Marcel Stevens

Marcel Stevens

Marcel has over 12 years in journalism who enjoys writing, jogging, reading and tennis.


Shares of GlaxoSmithKline, Sanofi and Haleon all marketed off sharply this week, shedding tens of billions in sector value, amid investor dread above potential U.S. litigation prices focused on well known heartburn drug Zantac.

This has been a known difficulty bumbling in the track record for several years but trader worry exploded this week in the direct-up to the to start with scheduled lawful continuing on Aug 22.

What is Zantac?

Company responses

What are the analysts expressing?

How large could the settlements be?

Comparison to Bayer, Monsanto